OOIR: Observatory of International Research

Papers

(The H4-Index of Hepatology International is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Gut microbiota alteration in hepatobiliary diseases: cause-and-effect relationship	120
Abstract	93
Is laparoscopic liver resection more suitable for diabetic patients with hepatocellular carcinoma? The debate continues	83
Obituary	75
Correction: Immunosuppression in adult liver transplant recipients: a 2024 update from the Italian Liver Transplant Working Group	71
New progress towards elimination of mother-to-child transmission of hepatitis B virus in China	63
Delicate and thin fibrous septa indicate a regression tendency in metabolic dysfunction-associated steatohepatitis patients with advanced fibrosis	63
Could the TAE score predicting the prognosis of unresectable HCC patients treated with TACE plus lenvatinib with PD-1 inhibitors be better if certain revisions are made?	54
Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma	54
Transjugular intrahepatic collateral-systemic shunt is effective for cavernous transformation of the portal vein with variceal bleeding	52
A preoperative scoring system to predict lymph node metastasis in intrahepatic cholangiocarcinoma	52
Consensus on the secondary prevention of primary liver cancer	51
Correction to: Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines	48
Correction to: Linking the gut and liver: crosstalk between regulatory T cells and mucosa-associated invariant T cells	47
Correction to: Serum interleukin-6 level predicts the prognosis for patients with alcohol-related acute-on-chronic liver failure	46
Diagnosis of significant liver fibrosis in patients with chronic hepatitis B using a deep learning-based data integration network	46
Prognosis factors of predicting survival in spontaneously ruptured hepatocellular carcinoma	41
PIVKA-II combined with alpha-fetoprotein for the diagnostic value of hepatic tumors in children: a multicenter, prospective observational study	40
Alcohol-related hepatitis admissions decline in 2021 after a 2020 surge attributed to the COVID-19 pandemic	40
Evaluation of the histologic and immunohistochemical (CD34, glutamine synthetase) findings in idiopathic non-cirrhotic portal hypertension (INCPH)	39
Incidence, risk factors, and outcomes of acute liver injury in hospitalized adults with acute kidney injury: a large multicenter study	38
Is lenvatinib in combination with transarterial chemoembolization benefit for unresectable hepatocellular carcinoma (uHCC)? The age interference needs to be eliminated	38
Reconsiderations for the liver donation from a living donor: addressing hepatic steatosis with weight loss preconditioning	37
Metabolically healthy obese and MAFLD: does weight status alone matter?	37
Development of a transformer model for predicting the prognosis of patients with hepatocellular carcinoma after radiofrequency ablation	34

Dairy products intake and prevalence, incidence, and recovery of non-alcoholic fatty liver disease in Chinese population	32
Etiologic fractions in patients of hepatocellular carcinoma in India with and without a background of cirrhosis: a multi-centric study	32
Midodrine plus propranolol versus propranolol alone in preventing first bleed in patients with cirrhosis and severe ascites: a randomized controlled trial	32
Clathrin light chain A facilitates small extracellular vesicle uptake to promote hepatocellular carcinoma progression	32
Acute-on-chronic liver failure in metabolic dysfunction-associated fatty liver disease patients: a disease multiplier	32
Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry	32